Laboratory-reflex cryptococcal antigen screening is associated with a survival benefit in Tanzania

Show simple item record

dc.contributor.author Faini, D
dc.contributor.author Kalinjuma, A. V,
dc.contributor.author Katende, A
dc.contributor.author Mbwaji, G
dc.contributor.author Mnzava, D
dc.contributor.author Nyuri, A
dc.contributor.author . Glass, T.R
dc.contributor.author Furrer, H
dc.date.accessioned 2021-11-09T10:44:57Z
dc.date.available 2021-11-09T10:44:57Z
dc.date.issued 2019
dc.identifier.uri http://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/2719
dc.description.abstract Background: Cryptococcal antigen (CrAg) screening in persons with advanced HIV/AIDS is recommended to prevent death. Implementing CrAg screening only in outpatients may underestimate the true CrAg prevalence and decrease its potential impact. Our previous 12-month survival/retention in CrAg-positive persons not treated with fluconazole was 0%. Methods: HIV testing was offered to all antiretroviral therapy– naive outpatients and hospitalized patients in Ifakara, Tanzania, followed by laboratory-reflex CrAg screening for CD4 ,150 cells/ mL. CrAg-positive individuals were offered lumbar punctures, and antifungals were tailored to the presence/absence of meningitis. We assessed the impact on survival and retention-in-care using multivariate Cox-regression models. Results: We screened 560 individuals for CrAg. The median CD4 count was 61 cells/mL (interquartile range 26–103). CrAg prevalence was 6.1% (34/560) among individuals with CD4 #150 and 7.5% among #100 cells/mL. CrAg prevalence was 2.3-fold higher among hospitalized participants than in outpatients (12% vs 5.3%, P = 0.02). We performed lumbar punctures in 94% (32/34), and 31% (10/34) had cryptococcal meningitis. Mortality did not differ significantly between treated CrAg-positive without meningitis and CrAg-negative individuals (7.3 vs 5.4 deaths per 100 person-years, respectively, P = 0.25). Independent predictors of 6-month death/lost to follow-up were low CD4, cryptococcal meningitis (adjusted hazard ratio 2.76, 95% confidence interval: 1.31 to 5.82), and no antiretroviral therapy initiation (adjusted hazard ratio 3.12, 95% confidence interval: 2.16 to 4.50). Conclusions: Implementing laboratory-reflex CrAg screening among outpatients and hospitalized individuals resulted in a rapid detection of cryptococcosis and a survival benefit. These results provide a model of a feasible, effective, and scalable CrAg screening and treatment strategy integrated into routine care in sub-Saharan Africa. en_US
dc.language.iso en en_US
dc.publisher CLINICAL SCIENCE en_US
dc.relation.ispartofseries Acquir Immune Defic Syndr;80(2)
dc.subject cryptococcal meningitis, en_US
dc.subject cryptococcal antigenemia, en_US
dc.subject HIV, fluconazole, en_US
dc.subject mortality, en_US
dc.subject sub-Saharan Africa en_US
dc.title Laboratory-reflex cryptococcal antigen screening is associated with a survival benefit in Tanzania en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MUHAS IR


Advanced Search

Browse

My Account